The current invention is provides methods for synthesizing inhibitors for RAD51 and inhibiting RAD51 protein activity. The compounds are designed to function as anticancer agents, either as monotherapies or combination therapies. This invention constitutes the design, synthesis and biological evaluation of small molecule inhibitors of a protein involved in DNA repair referred to as RAD51. These compounds are some of the first reported RAD51 inhibitors that have been demonstrated to work in cells. Nelson Grihalde grihalde@otm.uic.edu 312-996-4129
Smart, interactive desk
May 8, 2023
No Comments
Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the